CTS Corp. (CTS) is Trading Lower on Unusual Volume for January 01

Equities Staff  |

CTS Corp. (CTS) experienced unusually high volume on Jan. 01, as the stock lost 2.76% to a closing price of $17.64. The stock saw 220,447 shares trade hands over the course of the day on 1,191 trades. Given that the stock’s average daily volume over the last month has been 87,535 shares a day, this represents a pretty substantial spike over the norm.

CTS Corp. has a P/B ratio of 1.95. It also has a P/E ratio of 21.5. The stock has traded between $20.25 and $15.30 over the last 52-weeks, its 50-day SMA is now $18.50, and its 200-day SMA $18.54.

CTS Corp is a designer and manufacturer of electronic components and sensors to OEMs in the automotive, communications, medical, defense and aerospace, industrial and computer markets. The Company manufactures products in North America, Europe and Asia.

Headquartered in Elkhart, IN, CTS Corp. has 2,948 employees and is currently under the leadership of CEO Kieran O'Sullivan.

For a complete fundamental analysis analysis of CTS Corp., check out Equities.com’s Stock Valuation Analysis report for CTS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

DirectView Holdings Inc

DirectView Holdings Inc designs and installs surveillance systems, digital video recording and services. The company through its subsidiaries operates within two divisions security and surveillance and video conferencing services.